Research and Technology

Scandion Oncology’s technology is dedicated to developing new cancer treatments that will overcome chemotherapy resistance for thousands of patients.

Scandion Oncology has two major assets under development, SCO-101 and SCO-201, and more than 800 analogues for the future. The target indications for the analogues are solid tumors.

In addition, Scandion Oncology has access to a screening platform of drug resistant cancer cells. This platform screens for the ability of analogues to restore drug sensitivity.

SCO-101

The first asset, SCO-101, is an oral formulation with no toxicity in Phase I trials.

As a first-in-class cancer treatment, it offers low cost and a fast track to results. SCO-101 comes attached to forceful and attractive patents.

Its target indications are metastatic breast cancer and metastatic colorectal cancer, with more indications likely to follow.

SCO-201

The second asset, SCO-201, is an oral formulation with pharmacokinetic in vivo data designed to reverse drug resistance by inhibition of an efflux pump. SCO-201 comes attached to forceful and attractive patents.

Its target indications will be within solid tumors.